Stock PRTA PROTHENA CORPORATION PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/06/2024 BST 		5-day change 1st Jan Change
21.48 USD +9.26% Intraday chart for Prothena Corporation plc +5.24% -40.89%
05-28 Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License MT
05-28 Prothena Announces Bristol Myers Squibb Opt-In for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Prothena : Corporate Overview
PU
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
BU
Prothena: Q1 Earnings Snapshot
AQ
Prothena : Corporate Overview
PU
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
BU
Prothena to Report First Quarter 2024 Financial Results on May 8
BU
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia and Lymphoma
AQ
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
BU
Prothena : Director's Report and Financial Statements for Fiscal Year 2023
PU
Prothena to Participate in Upcoming Healthcare Conferences
BU
Prothena Appoints David Ford to Newly Created Chief People Officer Position
BU
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
BU
Prothena: Q4 Earnings Snapshot
AQ
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
BU
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
BU
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
BU
Prothena: Q3 Earnings Snapshot
AQ
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
BU
Prothena to Report Third Quarter 2023 Financial Results on November 2
BU
AL Amyloidosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRTA Stock
  4. News Prothena Corporation plc
  5. Press Releases